Christopher Kirk, Ph.D.

Christopher Kirk, Ph.D., is co-founder, President and Chief Scientific Officer, of Kezar Life Sciences (NASDQ : KZR), a clinical-stage, San Francisco Bay Area-based biotechnology company focused on drug discovery and development in autoimmunity and oncology. Prior to Kezar, he was the Vice President of Research at Onyx Pharmaceuticals where he played a key leadership role in the discovery and development of 2 proteasome inhibitors, carfilzomib (KYPROLIS™), currently approved for the treatment of multiple myeloma, and oprozomib, currently in Phase 2 testing. Dr. Kirk has authored multiple publications in journals including Cell, Nature Medicine, and Nature Reviews and is listed as an inventor on over 25 patents. He sits on the scientific advisory board at Karyopharm Therapeutics, Inc., Avidity Biosciences LLC, Rain Therapeutics, Inc., and the Institute of Applied Clinical Science at the M.D. Anderson Cancer Center. Dr. Kirk received his B.S. degree in Biochemistry from University of California, Davis, and his Ph.D. degree in Cellular and Molecular Biology from the University of Michigan.